Bibliografia

1. Basit S.  Vitamin D in health and disease: a literature review. BRITISH JOURNAL OF BIOMEDICAL SCIENCE 2013; 70 (4)
2. Malluche HH, Mawad H, Koszewski NJ. Update  on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure. Kidney International 2002; 62:367-374.
3. Gittoes NJL. Vitamin D – what is normal according to latest research and how should we deal with it? Clinical Medicine 2016; 16(2):171-4
4. Proietti A, D’Urso R, Cardelli P et al. Vitamina D: dalle problematiche di dosaggio alle implicazioni cliniche. G Gerontol 2014;62:142-149
5. Wacker M, Holick MF. Vitamin D-Effects on Skeletal and Extraskeletal Health and the Need for  Supplementation. Nutrients 2013; 5:111-14
6. Falchetti A, Rossi E, Cosso R et al. Vitamin D and Bone Health. Food and Nutrition Sciences 2016; 7:1033-1051.
7. Schacht E et al. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 2005; 5(3):273-284
8. Ringe JD et at. Alfacalcidol Versus Plain Vitamin D in the Treatment of Glucocorticoid/Inflammation-Induced Osteoporosis. J Rheumatol 2005; 32 Suppl 76:33-40.
9. Ringe JD et al. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol Int 2013; 33:637-643.
10. Felsenberg D et al. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact 2011; 11(1):34-45.
11. Richy F, Deroisyn R, Lecart M-P et al. D-Hormone analog alfacalcidol:an update on its role in postmenopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res 2005; 17:133-142.
12. Shao H-B et al. Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. Int J Clin Exp Med 2015; 8(8):12935-12941.
13. Nakamura Y et al. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis. Tohoku J. Exp. Med 2017; 241:319-326.
14. Schacht E et al. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int 2012; 32:207-215.
15. Hara S et al. Effects of Alfacalcidol on Back Extensor Strength Gained Through Back Extensor Exercise in Postmenopausal Women with Osteoporosis. Am J Phys Med Rehabil 2013; 92(2):101-10.
16.  Ito S et al. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: An investigation using a patient database. Geriatr Gerontol Int 2014; 14 (Suppl. 1):122-128.
17. Munisamy S, Daud KM, Mokhtar SS. Effects of 1alpha-Calcidol (Alfacalcidol) on Microvascular Endothelial Function, Arterial Stiffness, and Blood Pressure in Type II Diabetic Nephropathy Patients. Microcirculation 2016; 23:53-61
18. Ataie-Jafari A et al. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr 2013; 32(6):911-7
19. Amani Ali, Sama S, Abbassi M et al. Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology April 2017.
20. Achiron A et al. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double blind placebo-controlled study. Mult Scler 2015; 21(6):767-75.
21. Gaál J, Lakos G, Szodoray P et al. Immunological and Clinical Effects of Alphacalcidol in Patients with Psoriatic Arthropathy: Results of an Open, Follow-up Pilot Study. Acta Derm Venereol 2009; 89:140-144.
22. Halabe AR et al. Hypoparathyroidism-a long term follow-up experience with 1 alpha-vitamin D3 therapy. Clin Endocrinol (Oxf) 1994; 40(3):303-7.

<< Torna alla Home